Legochem Biosciences, Inc.

Legochem Bioscience Ltd.

The Green Cross Corporation

Ligachem Biosciences Inc.

Other

Novimmune Sa

Neopharm Co., Ltd.

Abl Bio Inc.

Yong Zu Kim

Ho Young Song

Jeiwook Chae

Chul-Woong Chung

Sung Ho Woo

Yeong Soo Oh

Tae Kyo Park

Yun Hee Park

Sang Eun Chae

Young Lag Cho

Hyang Sook Lee

Sung Min Kim

Sung Yoon Baek

Jeong Hee Ryu

Hyo Jung Choi

Ji Young Min

Dae Yon Lee

Kyung Eun Park

Kyu Man Oh

Ji Eun Jung

Su In Lee

Hyun Jin Kwon

Hyoungrae Kim

Sun Young Kim

Jong Un Cho

Dong Hyun Woo

Dae Hyuck Kang

Doo Hwan Jung

Ji Hye Oh

Jinyeong Kim

Jeon Yang

Byung Soo Lee

Ju Young Lee

Ju Hyun Park

Yoon Jeong Choi

Yun Ki Kim

Yeon Ok Kim

Ju Hyun Shin

Hyeun Joung Lee

Eun Mi Jung

Eun Hye Yang

Eun Hye Ban

Min Soo Kim

Suk Ho Lee

Hyoung Rae Kim

Seong Jin Kim

Hye Jin Heo

Hong Bum Lee

Yun-Hee Park

Hye Kyung Chang

Joung Yul Yun

Juyuel Baek

Soo Bong Ha

Hyun Min Ryu

Sang Hui Jo

Nicolas Fischer

Sang Woo Park

Chul Soon Park

Juhee Kim

Bora Lee

Jinhwa Lee

Jeung Hie Choi

Soongyu Choi

Yangsoon Lee

Se Kyoo Jeong

Yong Koo Kang

Byungje Sung

Hong Woo Lee

Kye-Jung Shin

Donghoon Yeom

Jinhyung Ahn

Kyungjin Park

Chang Sun Lee

Jeong Eun Jeon

Byeong Deog Park

Jiseon Yoo

Daehae Song

Jaehyun Eom

Kyuman Oh

Minji Park

Il Hong Suh

Yoo Hoon Kim

Jungsub Choi

Young Jae Yang

JinWon Jung

Sang Joo Lee

Yong Ho Chung

Hyung Mook Choi

Jeung Soon Choi

Jae Doo Huh

Uk Il Kim

Dong Kin Kim

Hee Sock Park

Ju Yuel Baek

Young-Jae Yang

So-Hyun Yoon

Nara Han

Ji-Na You

Youngeun Hong

The present invention relates to a pyrrolobenzodiazepine dimer prodrug and a ligand-linker conjugate compound thereof, a composition containing these, and therapeutic use thereof particularly as an anticancer drug. The stability of the compounds themselves and the stability thereof in plasma are excellent and the compounds are advantageous in terms of manifestation of toxicity, and thus the compounds are industrially useful in that it is possible to target proliferative diseases such as cancer, to perform a specific treatment, to maximize the drug efficacy, and to minimize the occurrence of side effects.

Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same

The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.

Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same

The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody.

Antibody-drug conjugates comprising branched linkers and methods related thereto

The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD19, as well as methods of making and using these anti-CD19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

Compositions and methods related to anti-CD19 antibody drug conjugates

The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

Antibody-drug conjugate comprising antibody against human ROR1 and use for the same

The present disclosure relates to pyrrolobenzodiazepine dimer prodrugs and ligand-linker conjugates thereof. The present disclosure also relates to compositions and uses of said prodrugs and conjugates.

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

Conjugates comprising self-immolative groups and methods related thereto

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

Conjugates comprising peptide groups and methods related thereto

Provided herein are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.

Compounds comprising self-immolative group

Provided are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.

Substituted dihydroisoxazole derivatives useful as inhibitors of &#x3b2;-lactamases are provided. The invention further provides medical uses of substituted dihydroisoxazole derivatives, for example, as antibacterial agents.

Compositions and methods for inhibiting &#x3b2;-lactamase

In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-CD19 antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

Growing community of inventors

Daejeon, South Korea

Yong Zu Kim